The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

Amgen and Kyowa Kirin have reported that the 24-week Phase III IGNITE trial assessing two dose strengths of rocatinlimab, in ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

AstraZeneca has reported positive “high-level” outcomes from the Phase III MATTERHORN trial of Imfinzi (durvalumab) with FLOT chemotherapy.

The trial enrolled 238 adults from 104 international sites, comprising 190 patients in the AChR+ group and 48 patients in the MuSK+ group. Credit: shutterstock / CGN089. Amgen’s Uplizna ...

Merck & Co (MSD) is looking to file for approval of its human immunodeficiency virus (HIV) treatment after two positive Phase III trial readouts. Its once-daily oral combination of the approved drug ...

Gilead presented the data at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). Image credit: Shutterstock / Sundry Photography Gilead is set to launch a Phase III trial of its ...

J&J and Protagonist Therapeutics are collectively developing icotrokinra, which is poised to be an immunology blockbuster. Image credit: Emily frost / Shutterstock. Johnson & Johnson (J&J) and ...

The trial aims to determine the recommended dose(s) for the therapy’s expansion when used as a single agent in adults. Credit: Ground Picture/Shutterstock. NiKang Therapeutics has concluded the first ...

Overall survival data was not yet mature with less than a quarter of the required number of events having occurred. Credit: Shutterstock / Maria Sbytova. Pharma giant Pfizer and Arvinas’s human ...